CJC-1295 w/ DAC

aka CJC-1295 with DAC · DAC:GRF

CAS 446262-90-4C165H269N47O46
limited evidenceResearch Only

CJC-1295 w/ DAC in brief

CJC-1295 w/ DAC (DAC:GRF): CJC-1295 with drug affinity complex, extending half-life to 5-8 days through albumin binding. Amino Axiom rates its evidence base limited. Its reported half-life is 5.8-8.1 days. It is filed under Growth Hormone in the Amino Axiom compound index. This summary reflects published research and is not medical advice.

Research data

Open any panel for the full data

Third-party creator videos and discussion, surfaced for research context. Amino Axiom does not endorse creator claims.

Long-form breakdowns

5 videos

Short-form clips

5 clips

Full Research Data

Overview

CJC-1295 with DAC incorporates a drug affinity complex (DAC) that binds to serum albumin, dramatically extending its half-life from 30 minutes to 5-8 days. This allows for weekly dosing. However, extended half-life may cause GH bleed rather than pulses, which may affect the natural GH secretion pattern.

PubMed results: 0 · Human studies: 0 · Animal studies: 0

Dosing Ranges

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

Based on pharmacokinetic studies

  • Subcutaneous Injection — standard range 1000-2000 mcg, Once weekly
Half-Life

5.8-8.1 days (high confidence)

Observed Benefits
  • Sustained growth hormone elevation via albumin binding (Limited): CJC-1295 with DAC incorporates a drug affinity complex that binds serum albumin, extending half-life to roughly 5–8 days in research descriptions and supporting prolonged GH-axis stimulation relative to short-acting GHRH analogs
  • Reduced administration frequency in research protocols (Limited): Extended pharmacokinetic profile has been studied as a basis for less frequent dosing schedules compared with non-DAC GHRH analogs that clear within about 30 minutes
  • GHRH receptor agonism (Strong preclinical): Research frames CJC-1295 as a modified GHRH analog that stimulates pituitary GH release through GHRH receptor pathways
Side Effects
  • Water retention and related GH-axis effects — Mild, Anecdotal. Anecdotal and limited clinical observations around prolonged GH elevation include fluid retention and related soft-tissue effects, consistent with broader GH secretagogue research
  • Injection site reactions — Mild, Anecdotal. Subcutaneous research use is associated with local injection-site reactions in anecdotal reports; formal human adverse-event datasets remain limited
Contraindications
  • Active malignancy (Theoretical / Preclinical): Sustained GH and IGF-1 pathway stimulation raises theoretical concern about growth-promoting effects in active neoplastic disease, a common caution in GH-axis research compounds
  • Concern for non-pulsatile GH elevation (Theoretical / Preclinical): Research commentary notes that multi-day half-life may produce continuous GH elevation rather than physiologic pulses, which may alter natural GH secretion patterns
Storage

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water